Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC Article (Web of Science)

Industry Collaboration International Collaboration

cited authors

  • Antonia, Scott J.; Balmanoukian, Ani; Brahmer, Julie; Ou, Sai-Hong I.; Hellmann, Matthew D.; Kim, Sang-We; Ahn, Myung-Ju; Kim, Dong-Wan; Gutierrez, Martin; Liu, Stephen V.; Schoffski, Patrick; Jaeger, Dirk; Jamal, Rahima; Jerusalem, Guy; Lutzky, Jose; Nemunaitis, John; Calabro, Luana; Weiss, Jared; Gadgeel, Shirish; Bhosle, Jaishree; Ascierto, Paolo A.; Rebelatto, Marlon C.; Narwal, Rajesh; Liang, Meina; Xiao, Feng; Antal, Joyce; Abdullah, Shaad; Angra, Natasha; Gupta, Ashok K.; Khleif, Samir N.; Segal, Neil H.

publication date

  • October 1, 2019

webpage

published in

category

keywords

  • Durvalumab
  • Efficacy
  • Immunotherapy
  • NSCLC
  • Safety

start page

  • 1794

end page

  • 1806

volume

  • 14

issue

  • 10